Zacks Investment Research Lowers Oxford BioMedica (OXBDF) to Hold

Oxford BioMedica (OTCMKTS:OXBDF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Separately, ValuEngine raised Oxford BioMedica from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.

Oxford BioMedica opened at $0.22 on Wednesday, according to MarketBeat.com. Oxford BioMedica has a 12-month low of $0.06 and a 12-month high of $0.45.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Get a free copy of the Zacks research report on Oxford BioMedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply